A Phase 1/2 interventional study of Biological NTLA-2002 and Normal Saline IV Administration in Hereditary Angioedema, sponsored by Intellia Therapeutics. Active, not recruiting at 9 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Intellia Therapeutics · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Angioedemas, Hereditary with a site in France — 8 open to participants now, 13 under way, 11 of them phase 3. Angioedemas, Hereditary · France.
Among the 38 studies in Angioedemas, Hereditary with a site in France, this one is the 24th largest by enrollment of the 28 interventional ones that give a count, is one of 6 that started in 2021, is the only one in phase 1/2, reaches primary completion later than 0 of the 12 other live ones, and was the 17th registered.
171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.
Browse Angioedemas, Hereditary studies →8 of the 38 studies in Angioedemas, Hereditary with a site in France are open now. Recruiting first, the newest first:
ADARx Pharmaceuticals, Inc. · Sites in France, United States, Argentina and 16 more countries
Ages 18+
Pharvaris Netherlands B.V. · Sites in France, United States, Australia and 13 more countries
Ages 18+
ADARx Pharmaceuticals, Inc. · Sites in France, United States, Argentina and 21 more countries
Ages 18+
Astria Therapeutics, Inc. · Sites in France, United States, Brazil and 15 more countries
Ages 12+
Pharvaris Netherlands B.V. · Sites in France, United States, Argentina and 20 more countries
Ages 12+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 23 · Phase 4 1
First in 2009; this study’s year is marked. 6 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is below the median of 48 across 116 interventional studies indexed under Angioedemas, Hereditary.
Median enrollment 103 across the 28 interventional studies, 194 across the 10 observational. Of the 24 that completed or were terminated, 9 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 38 have an industry lead sponsor. The 10 most frequent:
Intellia Therapeutics is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Intellia Therapeutics has 3 studies filed under Angioedemas, Hereditary — fewer than ten, so there is no comparison to draw.
5 of the studies in Angioedemas, Hereditary with a site in France that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06842823Phase 3Astria Therapeutics, Inc.A Study of Navenibart in Participants With Hereditary Angioedema | 2026-12 |
| NCT05392114Phase 3Ionis Pharmaceuticals, Inc.A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE) | 2026-12 |
| NCT05396105Phase 3Pharvaris Netherlands B.V.Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema | 2027-06 |
| NCT07266805Phase 3Pharvaris Netherlands B.V.Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency | 2027-06 |
| NCT06960213Phase 3ADARx Pharmaceuticals, Inc.STOP-HAE: A Phase 3 Study of ADX-324 in HAE | 2027-11-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 38 studies in Angioedemas, Hereditary with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will be conducted to evaluate the safety, tolerability, activity, pharmacokinetics, and pharmacodynamics of NTLA-2002 in adults with Hereditary Angioedema (HAE).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to 1 of 3 dose-escalation cohorts will receive a single dose of NTLA-2002 on Day 1 and will then be followed for 104 weeks. Primary observation period is 16 weeks.
Biological: Biological NTLA-2002
Participants randomized to NTLA-2002 (2 dose levels), will receive a single dose of NTLA-2002 on Day 1 and will then be followed for 104 weeks. Primary observation period is 16 weeks.
Biological: Biological NTLA-2002
Participants randomized to placebo will receive IV normal saline on Day 1 and will then be followed for up to 104 weeks. Primary observation period is 16 weeks.
Other: Normal Saline IV Administration
Participants assigned to this Substudy Arm (participants who previously received either 25mg or placebo only) will have the opportunity to receive a single dose of NTLA-2002 (50mg) and will then be followed for 52 weeks.
Biological: Biological NTLA-2002
CRISPR/Cas9 gene editing system delivered by LNP for IV administration
The administration of IV normal saline
Safety and tolerability of NTLA-2002 as determined by adverse events (AEs) and dose limiting toxicities (DLTs)
(Phase 1 only)
Time frame: From NTLA-2002 infusion up to week 104 post-infusion
Number of HAE attacks per month (Weeks 1-16)
(Phase 2 only)
Time frame: From study drug infusion up to week 16 post-infusion
Change from baseline in total plasma kallikrein protein level
(Phase 1 \& 2)
Time frame: From NTLA-2002 infusion up to week 104 post-infusion
Plasma and urine concentrations for DMG-PEG2k, LP000001, Cas9 mRNA, and sgRNA
(Phase 1 \& 2)
Time frame: From NTLA-2002 infusion up to week 104 post-infusion
Safety and tolerability of NTLA-2002 as determined by AEs
(Phase 2 only)
Time frame: From study drug infusion up to week 104 post-infusion
Number of HAE attacks per month (Weeks 5-16)
(Phase 2 only)
Time frame: From week 6 post-infusion up to week 16 post-infusion
Number of HAE attacks per month requiring acute therapy (Weeks 1-16, Weeks 5-16)
(Phase 2 only)
Time frame: From study drug infusion up to week 16 post-infusion
Plan to share: No
Ran from Dec 2021 to primary completion in Apr 2024, 27 months.
Completion moved once since we started tracking on Sep 25, 2026: Jul 2026 → May 2027, on Sep 25, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Intellia Therapeutics